Acadia Pharmaceuticals, Inc. - Earning & Dividend Analysis Snapshot

This detailed Report provides an Earnings and Dividends history for Acadia Pharmaceuticals, Inc.. Tabular results include up to a ten-year history of "as reported" Earnings per Share and Dividends per Share plus a calculation of the amount of earnings paid out over the year in dividends (i.e. Payout Ratio). Earnings and Dividends are presented on both a Quarterly and Annual basis. An annual Percent Change factor is calculated for both Earnings and Dividends.

Acadia Pharmaceuticals, Inc.. The Group's principal activity is to discover, develop and commercialize small molecule drugs for the treatment of central nervous system disorders.It has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma both in collaboration with Allergan Inc and ACP-106 in IND-track development. The Group currently developing a portfolio consisting of four most advanced product candidates including pimavanserin, which is in Phase III development for the treatment of Parkinson's disease psychosis and retained worldwide commercialization rights to pimavanserin. It operates in the United States and Europe.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report